An oil processing facility at Abqaiq and the nearby Khurais oil field was attacked on Saturday.Marketsread more
"There is reason to believe that we know the culprit," Trump said in a post on Twitter.Politicsread more
Brent crude surged by as much as 19.5% to reach $71.95 per barrel on Monday, the biggest intra-day jump since the Gulf War in 1991.Oilread more
The strike, depending on its length, could easily cost GM hundreds of millions of dollars. The last time the union declared a strike at GM was in 2007.Autosread more
Saudi Aramco has 35-40 days of supply to meet contractual obligations, a source close to the matter told CNBC.Energyread more
The trucking industry is worth hundreds of billions of dollars per year. Uber is going after this market with Uber Freight, an online platform that matches truckers with...Technologyread more
OxyContin maker Purdue Pharma filed for Chapter 11 bankruptcy protection on Sunday.Health and Scienceread more
Saudi Arabia on Saturday shut down half its oil production after a series of drone strikes hit the world's largest oil processing facility in an attack claimed by Yemen's...Futures & Commoditiesread more
U.S. stock futures sank amid fears that a surge in oil prices following an attack in Saudi Arabia could slow down global economic growth.Marketsread more
The recommendations include changing corporate reporting structures, creating a new safety group, and changing the cockpits of future planes to accommodate new pilots with...Aerospace & Defenseread more
The state would become the second in the country, behind Michigan, to ban the sale of fruit flavored e-cigarettes, which are popular with teenagers.Health and Scienceread more
Former Food and Drug Administration Commissioner Scott Gottlieb defended his decision to join Pfizer's board of directors just two months after stepping down from the agency that regulates the drugmaker. He said in an interview Tuesday on CNBC he feels "very confident" about his record at the FDA and is "very proud" of his new role.
Pfizer last week announced Gottlieb would join its board of directors — a job that paid a minimum of $335,000 in stock and cash in 2018, according to a regulatory filing. At the FDA, Gottlieb called for promoting innovation and increasing competition to lower prescription drug prices.
"I feel very confident about my record at the agency, and I called balls and strikes and acted in the interest of public health and public interest," Gottlieb said in an interview on CNBC's "Squawk Box."
Gottlieb, who is a medical doctor, previously worked in the biotech sector as a venture capitalist. "I've largely returned to my work prior to the FDA," he said.
Since leaving the agency, Gottlieb has returned to the American Enterprise Institute as a resident fellow and as a special partner at venture capital firm New Enterprise Associates, where he worked before joining the FDA. He also joined CNBC as a contributor.
It's not uncommon for government officials to join the sector they regulated after leaving the administration. However, President Donald Trump, who appointed Gottlieb, has made "draining the swamp" one of his main priorities.
"I worked with some large drugmakers before I came into the agency," Gottlieb said, adding that his new role at Pfizer is bigger than anything he did before the FDA. "I made no bones about the fact that I had expertise in life sciences and I made my living trying to promote innovation in this sector prior to coming to the agency."
Disclosure: Scott Gottlieb is a CNBC contributor.